No Data
C.Q. Pharmaceutical Holding (000950.SZ): C.Q. Pharmaceutical plans to register accounts receivable asset securitization products not exceeding 3 billion yuan.
On March 7th, Gelonghui reported that C.Q. Pharmaceutical Holding (000950.SZ) announced that to further strengthen accounts receivable management and optimize the asset-liability structure, its subsidiary Chongqing Pharmaceutical (Group) Co., Ltd. (referred to as "C.Q. Pharmaceutical") intends to register accounts receivable asset securitization products (including but not limited to asset-backed securities special plans, asset-backed commercial paper, or accounts receivable debt financing plans, etc.) on platforms such as the Shenzhen Stock Exchange, Shanghai Stock Exchange, Bank Of China Interbank Market Traders Association, or Peking Financial Assets Exchange in the year 2025 or directly to.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
C.Q. Pharmaceutical Holding Co., Ltd. (SZSE:000950) Screens Well But There Might Be A Catch
Heavy Pharmaceuticals Holdings: 2024 Annual Results Forecast
C.Q. Pharmaceutical Holding (000950.SZ) issued a profit warning, expecting net income between 0.29 billion yuan and 0.39 billion yuan, a year-on-year decline of 40.45% to 55.72%.
C.Q. Pharmaceutical Holding (000950.SZ) disclosed its performance forecast for 2024, with the company expecting profits attributable to Shareholders of the listed company...
C.Q. Pharma's Unit Gets Drug Registration Certificate for Mirabegron Tablets
The Returns At C.Q. Pharmaceutical Holding (SZSE:000950) Aren't Growing
